JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Current Perspectives on Drug-Induced Nephrotoxicity

Ritesh Ksheerasagar*[1], Laxmi Pattanashetti[2]

[1] *Research Scholar, Department of Pharmacology, KLE College of Pharmacy, Hubballi, Karnataka, India*
[2] *Assistant Professor, Department of Pharmacology, KLE College of Pharmacy, Hubballi, Karnataka, India*

Publication history: Received on 21st Mar 2025; Revised on 8th April 2025; Accepted on 16th April 2025

Article DOI: 10.69613/nkjgsh79

Abstract: Nephrotoxicity is characterized by kidney injury resulting from exposure to various therapeutic agents and environmental toxins. The kidney's unique anatomical and physiological features make it particularly vulnerable to toxic insults through multiple pathways, including direct tubular damage, oxidative stress, inflammation, and vascular injury. Common nephrotoxic agents encompass aminoglycoside antibiotics, nonsteroidal anti-inflammatory drugs, radiocontrast media, chemotherapeutic agents, and heavy metals. Recent advances in molecular biology have enhanced our knowledge of cellular mechanisms underlying nephrotoxic injury, revealing complex interactions between drug metabolism, cellular stress responses, and tissue repair pathways. Novel biomarkers like kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and interleukin-18 show promise for early detection of kidney injury, potentially enabling timely intervention before irreversible damage occurs. Prevention measures focus on risk assessment, drug dosing optimization, and protective interventions, while management approaches include therapeutic drug monitoring, supportive care, and targeted therapies. Emerging technologies in artificial intelligence and pharmacogenomics offer new possibilities for predicting individual susceptibility to nephrotoxicity and personalizing treatment approaches. Significant challenges remain in early detection, risk stratification, and development of effective nephroprotective agents despite the recent progress.

Keywords: Nephrotoxicity; Drug-induced kidney injury; Biomarkers; Nephroprotection; Pharmacogenomics.

1. Introduction

Drug-induced nephrotoxicity poses a significant medical challenge, affecting approximately 14-26% of hospitalized patients and contributing to increased healthcare costs, prolonged hospital stays, and adverse clinical outcomes. The kidney's vulnerability to toxic injury stems from its unique physiological roles in drug excretion, concentration of toxins, and metabolic processing of potentially harmful substances [1]. The complexity of nephrotoxicity mechanisms has evolved significantly since early observations. While initial research focused primarily on direct cellular damage, recent molecular studies have revealed intricate pathways involving oxidative stress, inflammatory cascades, and cellular death mechanisms [2]. These findings have transformed our perspective on drug-induced kidney injury from a simple toxin-mediated process to a complex interplay of multiple pathophysiological mechanisms [3]. Aminoglycoside antibiotics represent a classic example of nephrotoxic agents, causing injury through direct tubular epithelial cell damage and generation of reactive oxygen species [4]. The accumulation of these drugs in proximal tubular cells leads to phospholipidosis, disruption of cellular membranes, and mitochondrial dysfunction, ultimately resulting in cell death [5].

The economic impact of drug-induced nephrotoxicity extends beyond immediate healthcare costs. Studies indicate that nephrotoxic acute kidney injury increases hospital costs by 2.4-fold and extends hospital stays by an average of 5-7 days [6]. Additionally, long-term consequences include an elevated risk of chronic kidney disease, cardiovascular complications, and reduced quality of life [7]. Modern therapeutic approaches have introduced new challenges in nephrotoxicity. The advent of targeted cancer therapies, novel antimicrobials, and immunomodulatory agents has created a complex landscape of potential renal injury mechanisms [8]. For instance, immune checkpoint inhibitors can induce unique patterns of kidney injury through immune-mediated mechanisms, requiring different preventive and management strategies compared to traditional nephrotoxic agents [9]. The role of genetic factors in nephrotoxicity susceptibility has gained increasing attention. Polymorphisms in drug-metabolizing enzymes, transporters, and stress-response proteins can significantly influence individual risk for kidney injury [10]. This genetic variability partly explains the differential susceptibility to nephrotoxic agents among patients receiving similar drug exposures [11]. Environmental factors and pre-existing conditions further complicate the nephrotoxicity landscape. Advanced age, diabetes, hypertension, and chronic kidney disease amplify the risk of drug-induced kidney injury, necessitating careful consideration in therapeutic decision-making [12]. The interaction between these factors and nephrotoxic agents creates a complex risk profile that requires individualized assessment and management strategies. The main objective of this paper is to describe the current literature and recent progress of the molecular mechanisms underlying drug-induced nephrotoxicity.

* Corresponding author: Ritesh Ksheerasagar

2. Mechanisms of Nephrotoxicity

2.1. Cellular and Molecular Pathways

The pathogenesis of drug-induced nephrotoxicity involves multiple cellular and molecular mechanisms that often operate simultaneously. At the cellular level, direct toxicity to tubular epithelial cells represents a primary mechanism of injury [13]. Proximal tubular cells are particularly susceptible due to their high metabolic activity and role in concentrating potentially toxic substances. These cells express numerous transporters that facilitate drug uptake, leading to accumulation of nephrotoxic compounds and subsequent cellular damage [14].

Oxidative stress emerges as a central mechanism in nephrotoxic injury. Many drugs trigger the generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS), overwhelming cellular antioxidant defenses. This oxidative burden leads to lipid peroxidation, protein modification, and DNA damage, ultimately resulting in cell death through both apoptotic and necrotic pathways [15].



Figure 1. Pathophysiological Mechanisms of Drug-Induced Nephrotoxicity

2.1.1. Mitochondrial Dysfunction

Mitochondrial injury plays a crucial role in nephrotoxicity. Many drugs directly impair mitochondrial function by disrupting electron transport chain complexes, leading to decreased ATP production and increased ROS generation. This energy deficit compromises cellular repair mechanisms and ion pump function, resulting in cellular swelling and death [16].

2.1.2. Inflammatory Responses

Drug-induced kidney injury often triggers a complex inflammatory cascade. The release of damage-associated molecular patterns (DAMPs) from injured cells activates innate immune responses, leading to recruitment of inflammatory cells and production of pro-inflammatory cytokines. This inflammatory response can amplify initial injury and impair tissue repair processes [17].

2.2. Vascular Mechanisms

2.2.1. Hemodynamic Alterations

Many nephrotoxic drugs affect renal blood flow and glomerular filtration. For instance, calcineurin inhibitors cause afferent and efferent arteriolar vasoconstriction, reducing glomerular filtration rate. NSAIDs disrupt the balance of vasodilatory prostaglandins, potentially leading to acute kidney injury, particularly in volume-depleted states [18].

2.2.2. Endothelial Injury

Direct endothelial cell injury represents another important mechanism of nephrotoxicity. Some drugs cause endothelial dysfunction, leading to altered vascular permeability, microthrombus formation, and tissue hypoxia. This vascular injury can initiate a cycle of inflammation and further tissue damage [19].

2.3. Immunological Mechanisms

Drug-induced kidney injury can involve both innate and adaptive immune responses. Some drugs act as haptens, binding to cellular proteins to form immunogenic complexes that trigger immune-mediated injury. This mechanism is particularly relevant in drug-induced interstitial nephritis, where T-cell-mediated responses play a central role [20].

3. Common Nephrotoxic Agents

3.1. Antimicrobial Agents

3.1.1. Aminoglycosides

Aminoglycoside antibiotics remain a significant cause of drug-induced nephrotoxicity, affecting 10-20% of patients receiving these agents. Gentamicin, tobramycin, and amikacin accumulate in proximal tubular cells through megalin-mediated endocytosis. Within cells, these drugs disrupt mitochondrial function, activate NADPH oxidases, and trigger lysosomal phospholipidosis. Risk factors include prolonged therapy duration, concurrent nephrotoxic medications, and pre-existing renal impairment [21].

3.1.2. Vancomycin

High-dose vancomycin therapy carries significant nephrotoxic potential, particularly when trough levels exceed 20 mg/L. The mechanism involves oxidative stress, mitochondrial dysfunction, and direct tubular injury. Recent studies indicate that crystal nephropathy may also contribute to vancomycin-induced kidney injury, especially with rapid infusion rates or high doses [22].

Table 1. Classification of Common Nephrotoxic Drugs and Their Primary Mechanisms of Injury

Drug Class	Examples	Primary Mechanism	Clinical Manifestation
Aminoglycosides	Gentamicin, Tobramycin	Proximal tubular toxicity, Oxidative stress	Acute tubular necrosis
Antifungals	Amphotericin B	Membrane permeability alteration	Tubular dysfunction
Chemotherapeutics	Cisplatin, Methotrexate	DNA cross-linking, Direct cellular toxicity	Acute kidney injury
NSAIDs	Ibuprofen, Naproxen	Prostaglandin inhibition	Prerenal failure, Interstitial nephritis
Contrast Media	Iodinated contrast	Vasoconstriction, Direct toxicity	Contrast-induced nephropathy
Calcineurin Inhibitors	Cyclosporine, Tacrolimus	Vasoconstriction, Fibrosis	Acute and chronic nephrotoxicity

3.2. Anti-neoplastic Agents

3.2.1. Platinum Compounds

Cisplatin stands as a prime example of nephrotoxic chemotherapy, causing dose-dependent kidney injury in up to 30% of patients. It accumulates in proximal tubular cells, forming DNA cross-links and triggering multiple cell death pathways. Carboplatin and oxaliplatin demonstrate lower nephrotoxicity profiles but still require careful monitoring [23].

3.2.2. Targeted Therapies

Modern targeted therapies present unique nephrotoxic challenges. Anti-VEGF agents like bevacizumab can cause thrombotic microangiopathy and proteinuria through endothelial injury. Tyrosine kinase inhibitors may lead to podocyte injury and nephrotic syndrome. Immune checkpoint inhibitors can trigger acute interstitial nephritis through T-cell-mediated mechanisms [24].

3.3. Anti-inflammatory Drugs

Non-steroidal anti-inflammatory drugs cause nephrotoxicity through multiple mechanisms. By inhibiting cyclooxygenase enzymes, they reduce prostaglandin synthesis, affecting renal blood flow and sodium homeostasis. Chronic NSAID use can lead to analgesic nephropathy, characterized by papillary necrosis and chronic interstitial nephritis [25].

3.4. Contrast Media

Iodinated contrast agents induce nephropathy through direct tubular toxicity and vascular effects. Risk factors include chronic kidney disease, diabetes mellitus, and reduced effective circulating volume. The development of iso-osmolar and low-osmolar contrast media has reduced but not eliminated this risk [26].

3.5. Calcineurin Inhibitors

Cyclosporine and tacrolimus cause both acute and chronic nephrotoxicity. Acute effects stem from afferent arteriolar vasoconstriction, while chronic toxicity involves interstitial fibrosis and tubular atrophy. Therapeutic drug monitoring and dose optimization remain crucial in preventing these complications [27].

3.6. Environmental Toxins

Lead, cadmium, and mercury exposure can cause progressive kidney damage. These metals accumulate in proximal tubular cells, disrupt mitochondrial function, and generate oxidative stress. Occupational exposure and environmental contamination remain significant sources of heavy metal nephrotoxicity [28]

4. Risk Factors

4.1. Patient-Related Factors

Age significantly influences nephrotoxicity risk, with elderly patients showing increased susceptibility due to reduced renal reserve, altered drug metabolism, and comorbid conditions. Similarly, very young patients may have increased vulnerability due to immature drug handling mechanisms and developing kidney function [29].

Pre-existing renal impairment markedly increases nephrotoxicity risk, creating a vicious cycle where compromised kidney function leads to altered drug handling and increased toxicity. Chronic kidney disease patients exhibit reduced nephron mass and impaired repair mechanisms, making them particularly vulnerable to additional kidney injury [30].



Figure 2. Risk Stratification and Prevention of Nephrotoxicity

4.2. Clinical Conditions

Diabetes mellitus represents a major risk factor through multiple mechanisms, including altered renal hemodynamics, increased oxidative stress, and enhanced inflammatory responses. Diabetic patients show heightened susceptibility to contrast-induced nephropathy and aminoglycoside toxicity [31].

Table 2. Risk Factors for Drug-Induced Nephrotoxicity

Category	Risk Factor	Relative Risk*
Patient-Related	Age >65 years	2.5
	Chronic kidney disease	3.8
	Diabetes mellitus	2.1
	Heart failure	1.8
Drug-Related	Multiple nephrotoxic agents	3.2
	High-dose therapy	2.7
	Extended duration	1.9
Clinical Conditions	Volume depletion	2.3
	Sepsis	3.5
	Hypotension	2.0

*Relative risk values are approximate and derived from multiple studies

Volume depletion, whether from dehydration, heart failure, or cirrhosis, significantly increases nephrotoxicity risk by reducing renal perfusion and concentrating potentially harmful substances within the kidney. This risk becomes particularly relevant with NSAIDs and radiocontrast agents [32].

4.3. Pharmacological Factors

Concurrent administration of multiple nephrotoxic agents creates synergistic toxicity risks. For instance, combining vancomycin with aminoglycosides or using NSAIDs with ACE inhibitors in volume-depleted states significantly increases kidney injury risk [33].

Drug dosing patterns, including total daily dose, frequency of administration, and duration of therapy, directly influence nephrotoxicity risk. Extended duration of aminoglycoside therapy and high vancomycin trough levels correlate with increased nephrotoxicity [34].

5. Diagnosis

5.1. Traditional Markers

5.1.1. Serum Creatinine

While widely used, serum creatinine shows significant limitations as a marker of acute kidney injury. Its delayed rise after injury (typically 24-48 hours) and dependence on muscle mass, age, and gender reduce its utility for early detection. Nevertheless, it remains valuable for monitoring trends and estimating glomerular filtration rate [35].

5.1.2. Blood Urea Nitrogen

BUN provides complementary information to creatinine but is influenced by numerous non-renal factors including protein intake, catabolic state, and volume status. The BUN/creatinine ratio helps differentiate pre-renal from intrinsic renal causes of kidney injury [36].

5.2. Novel Biomarkers

KIM-1 is a highly specific marker of proximal tubular injury, showing rapid upregulation following toxic exposure. Its presence in urine precedes creatinine elevation and correlates with injury severity. NGAL, expressed by damaged tubular cells, serves as an early indicator of kidney injury, particularly useful in monitoring cisplatin nephrotoxicity [37].

Table 3. Biomarkers for Early Detection of Nephrotoxicity

Biomarker	Sample Type	Time to Detection	Specificity	Clinical Utility
KIM-1	Urine	6-12 hours	High	Proximal tubular injury
NGAL	Urine/Plasma	2-4 hours	Moderate	Early AKI detection
IL-18	Urine	12-24 hours	High	Inflammatory injury
Cystatin C	Serum	24-48 hours	High	GFR estimation
NAG	Urine	12-24 hours	Moderate	Tubular damage
L-FABP	Urine	4-6 hours	Moderate	Tubular stress

5.3. Functional Markers

Cystatin C, produced at a constant rate by nucleated cells, provides a more accurate estimation of glomerular filtration rate than creatinine, especially in elderly patients and those with reduced muscle mass. IL-18 levels in urine indicate tubular inflammation and predict acute kidney injury severity [38].

5.4. Advanced Imaging

Novel imaging techniques, including magnetic resonance imaging with specific contrast agents and positron emission tomography, offer promising approaches for early detection of nephrotoxicity. These methods can reveal subtle changes in renal perfusion and metabolism before functional decline becomes apparent [39].

6. Prevention and Management

6.1. Risk Assessment

Systematic evaluation of patient-specific risk factors before initiating potentially nephrotoxic therapy forms the cornerstone of prevention. This includes assessment of baseline renal function, comorbidities, concurrent medications, and genetic factors when

applicable. Development of risk prediction models incorporating these factors helps guide therapeutic decision-making and monitoring intensity [40].

6.2. Dose Optimization

Implementation of dosing protocols based on patient characteristics and therapeutic drug monitoring significantly reduces nephrotoxicity risk. For aminoglycosides, extended-interval dosing regimens demonstrate reduced toxicity while maintaining antimicrobial efficacy. Similarly, weight-based dosing and careful monitoring of trough levels for vancomycin optimize therapeutic outcomes [41].

6.3. Hydration

Appropriate volume status maintenance plays a crucial role in nephrotoxicity prevention. For contrast-induced nephropathy, standardized hydration protocols using isotonic saline or sodium bicarbonate solutions, initiated before contrast exposure, significantly reduce injury risk. Similar principles apply to cisplatin administration, where vigorous hydration remains essential [42].

7. Pharmacological Interventions

7.1. Antioxidant therapy

N-acetylcysteine shows promise in preventing contrast-induced nephropathy through its antioxidant properties and enhancement of nitric oxide-mediated vasodilation. Other antioxidants, including vitamin C and alpha-lipoic acid, demonstrate varying degrees of nephroprotection in experimental models [43].



Figure 3. Clinical Approach to Managing Drug-Induced Nephrotoxicity

7.2. Anti-inflammatory Agents

Targeted anti-inflammatory interventions, particularly in immune-mediated nephrotoxicity, can mitigate kidney injury. Corticosteroids play a crucial role in managing drug-induced interstitial nephritis, while specific cytokine inhibitors show promise in experimental models [44].

8. Therapeutic Monitoring

8.1. Biomarker-Guided Therapy

Integration of novel biomarkers into clinical practice enables early detection of kidney injury and guides therapeutic modifications. Serial monitoring of urinary KIM-1 and NGAL levels helps identify subclinical injury before significant functional decline occurs [45].

8.2. Drug Level Monitoring

Regular monitoring of drug levels, particularly for agents with narrow therapeutic windows, allows for precise dose adjustments. This approach proves especially valuable for aminoglycosides, vancomycin, and calcineurin inhibitors [46].

8.3. Supportive Care

8.3.1. Renal Replacement Therapy

When severe nephrotoxicity occurs, timely initiation of renal replacement therapy can be life-saving. The choice between intermittent hemodialysis and continuous renal replacement therapy depends on hemodynamic stability and other clinical factors [47].

8.3.2. Nutritional Support

Optimization of nutritional status supports renal recovery. Protein intake modification, micronutrient supplementation, and maintenance of appropriate caloric intake contribute to improved outcomes [48].

8.4. Long-term Management

8.4.1. Monitoring for Chronic Effects

Regular assessment of renal function after nephrotoxic injury helps identify patients at risk for chronic kidney disease. Long-term follow-up enables early intervention for progressive renal dysfunction [49].

8.4.2. Risk Mitigation

Implementation of preventive strategies for future exposures, including medication alternatives, dose modifications, and enhanced monitoring protocols, reduces recurrent injury risk [50].

9. Conclusion

Drug-induced nephrotoxicity is a significant clinical challenge with far-reaching implications for patient care and healthcare systems. Recent advances in biomarker development and risk prediction models have enhanced our ability to detect and prevent kidney injury, yet significant challenges persist. The evolution of therapeutic agents introduces new nephrotoxicity patterns requiring continuous adaptation of monitoring and prevention strategies. The role of genetic factors in determining individual susceptibility to nephrotoxicity shows the importance of personalized medicine approaches in preventing and managing kidney injury. Effective management of drug-induced nephrotoxicity requires careful risk assessment, proactive monitoring, and timely intervention. The usage of novel biomarkers with traditional monitoring parameters offers improved sensitivity for early detection, while standardized prevention protocols help mitigate injury risk in vulnerable populations. Supportive care including appropriate fluid management and nutritional support, play crucial roles in optimizing outcomes. Success in reducing the burden of drug-induced nephrotoxicity ultimately depends on maintaining a balance between therapeutic efficacy and renal safety.

References

[1] Sales GT, Foresto RD. Drug-induced nephrotoxicity. Rev Assoc Med Bras. 2020;66(1):82-90.

[2] Perazella MA. Drug-induced nephrotoxicity: pathophysiology and prevention. Nat Rev Nephrol. 2023;19(1):25-38.

[3] Awdishu L, Mehta RL. The 6R's of drug induced nephrotoxicity. BMC Nephrol. 2017;18(1):124.

[4] McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M. Aminoglycoside-induced nephrotoxicity in children. Pediatr Nephrol. 2017;32(11):2015-25.

[5] Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity. Kidney Int. 2011;79(1):33-45.

[6] Mehta RL, Pascual MT, Soroko S, Chertow GM. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288(20):2547-53.

[7] Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442-8.

[8] Perazella MA, Shirali AC. Nephrotoxicity of cancer immunotherapies: past, present and future. J Am Soc Nephrol. 2018;29(8):2039-52.

[9] Shingarev R, Glezerman IG. Kidney complications of immune checkpoint inhibitors: a review. Am J Kidney Dis. 2019;74(4):529-37.

[10] Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115-24.

[11] Teaford HR, Barreto JN, Vollmer KJ, Rule AD, Barreto EF. Cisplatin-induced nephrotoxicity: a review of preventive strategies. Mayo Clin Proc. 2020;95(12):2756-66.

[12] Kashani K, Cheungpasitporn W, Ronco C. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption. Clin Chem Lab Med. 2017;55(8):1074-89.

[13] Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest. 2011;121(11):4210-21.

[14] Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury. Lancet. 2022;400(10357):1068-84.

[15] Dennis JM, Witting PK. Protective role for antioxidants in acute kidney disease. Nutrients. 2017;9(7):718.

[16] Mehta RL, Awdishu L, Davenport A, Murray PT, Macedo E, Cerda J, et al. Phenotype standardization for drug-induced kidney disease. Kidney Int. 2015;88(2):226-34.

[17] Ostermann M, Joannidis M. Acute kidney injury 2016: diagnosis and diagnostic workup. Crit Care. 2016;20(1):299.

[18] Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol. 2021;61(S2):S28-S47.

[19] Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury. Compr Physiol. 2012;2(2):1303-53.

[20] Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6(8):461-70.

[21] Ranganathan P, Mohamed S, Jayakumar C, Ramesh G. Molecular mechanisms of nephrotoxicity: insights from preclinical studies. Toxicol Res. 2019;35(1):1-7.

[22] van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734-44.

[23] Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010;2(11):2490-518.

[24] Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant. 2017;32(6):936-49.

[25] Dreischulte T, Morales DR, Bell S, Guthrie B. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney Int. 2015;88(2):396-403.

[26] McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, et al. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2016;68(13):1465-73.

[27] Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481-508.

[28] Tchounwou PB, Yedjou CG, Patlolla AK, Sutton DJ. Heavy metal toxicity and the environment. Exp Suppl. 2012;101:133-64.

[29] Anderson S, Eldadah B, Halter JB, Hazzard WR, Himmelfarb J, Horne FM, et al. Acute kidney injury in older adults. J Am Soc Nephrol. 2011;22(1):28-38.

[30] James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet. 2010;375(9722):1296-309

[31] Giunti S, Barit D, Cooper ME. Mechanisms of diabetic nephropathy: role of hypertension. Hypertension. 2006;48(4):519-26.

[32] Ejaz AA, Mohandas R. Are diuretics harmful in the management of acute kidney injury? Curr Opin Nephrol Hypertens. 2014;23(2):155-60.

[33] Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2020;71(6):1361-4.

[34] Daniels LB, Barrett-Connor E, Clopton P, Laughlin GA, Ix JH, Maisel AS. Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults. J Am Coll Cardiol. 2012;59(12):1101-9.

[35] Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.

[36] Ostermann M, Philips BJ, Forni LG. Clinical review: Biomarkers of acute kidney injury: where are we now? Crit Care. 2012;16(5):233.

[37] Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol. 2008;48:463-93.

[38] Shlipak MG, Mattes MD, Peralta CA. Update on cystatin C: incorporation into clinical practice. Am J Kidney Dis. 2013;62(3):595-603.

[39] Prasad PV, Cannillo J, Chavez DR, Pincus E, Haque ME, Li W, et al. First-pass renal perfusion imaging using MR arterial spin labeling at 3 Tesla. Invest Radiol. 2016;51(8):520-6.

[40] Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17(1):R25.

[41] Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients. Am J Health Syst Pharm. 2009;66(1):82-98.

[42] Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy. Arch Intern Med. 2002;162(3):329-36.

[43] Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180-4.

[44] Gonzalez E, Gutierrez E, Galeano C, Chevia C, de Sequera P, Bernis C, et al. Early steroid treatment improves renal function recovery in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73(8):940-6.

[45] Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt H, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury. JAMA. 2016;315(20):2190-9

[46] Goldstein SL, Chawla L, Ronco C, Kellum JA. Renal recovery. Crit Care. 2014;18(1):301.

[47] Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med. 2016;375(2):122-33.

[48] Fiaccadori E, Regolisti G, Maggiore U. Specialized nutritional support interventions in critically ill patients on renal replacement therapy. Curr Opin Clin Nutr Metab Care. 2013;16(2):217-24.

[49] See EJ, Jayasinghe K, Glassford N, Bailey M, Johnson DW, Polkinghorne KR, et al. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int. 2019;95(1):160-72.

[50] Kellum JA, Prowle JR. Paradigms of acute kidney injury in the intensive care setting. Nat Rev Nephrol. 2018;14(4):217-30.